Mounjaro vs Zepbound (2026): tirzepatide split by indication

Same molecule, different indications, same dose ladder

Mounjaro and Zepbound are both tirzepatide manufactured by Eli Lilly. Unlike Wegovy/Ozempic where the dose ranges differ, Mounjaro and Zepbound share the identical dose ladder: 2.5mg → 5mg → 7.5mg → 10mg → 12.5mg → 15mg weekly, titrated every 4 weeks. Same molecule, same pen, same dose options.

The split is regulatory: Mounjaro is approved for type 2 diabetes (May 2022). Zepbound is approved for chronic weight management in adults with obesity or overweight with weight-related comorbidity (December 2023), plus a 2024 expansion to include moderate-severe obstructive sleep apnea in adults with obesity.

The OSA indication is unique

Zepbound's December 2024 FDA expansion to obstructive sleep apnea (OSA) in adults with obesity is the first time a GLP-1 received OSA approval. The SURMOUNT-OSA trial showed ~50% reduction in apnea-hypopnea index alongside ~17% weight loss. This creates a clinical pathway where patients with both obesity and OSA can be prescribed Zepbound on either indication — and notably, payers may cover the OSA indication when they exclude weight-loss coverage.

Mounjaro does not have this OSA indication. Patients with T2D + obesity + OSA are likely better served by Zepbound for the OSA pathway, even if they have T2D as well.

Insurance landscape

Mounjaro covered broadly on T2D formularies. PA typically requires T2D diagnosis + A1C documentation. $25-50 copay common after PA.

Zepbound coverage varies. Commercial plans that include obesity medications generally cover it after PA. Plans that exclude obesity medications don't cover it for weight loss but may now cover it for OSA (this is evolving rapidly through 2026). Medicare does not currently cover weight-loss-only indications.

Notable: when patients have both T2D and obesity, insurance may push them to Mounjaro purely for coverage reasons even though Zepbound would access the same molecule at the higher 15mg dose with explicit weight-management indication. Documentation matters for which path actually gets approved.

Cost comparison

Retail list price approximately equivalent — both around $1,070/month for the pen at any dose.

Commercial insurance with PA: $25-50/mo copay for either.

Cash-pay paths: LillyDirect offers Zepbound single-dose vials at $349-549/month (depending on dose strength) for eligible cash patients. This is a substantial cost reduction vs the pen form. Lilly also offers some patient assistance for Mounjaro but the vial-direct-pay model is Zepbound-specific currently.

For self-pay or coverage-excluded patients, Zepbound vials via LillyDirect are usually the cheapest legitimate path to tirzepatide.

Efficacy expectations

SURMOUNT-1 trial (Zepbound for obesity): mean weight loss 22.5% at 72 weeks for the 15mg dose. This is the highest weight-loss result reported for any approved GLP-1.

SURPASS trial program (Mounjaro for T2D): A1C reduction 1.8-2.4% across dose levels; weight loss as secondary outcome was 11-15% depending on baseline.

These differences reflect trial populations (T2D vs obesity without diabetes) more than drug differences. Same molecule, same dose, different patient populations produce somewhat different magnitude of weight loss.

Switching between them

Patient on Mounjaro 10mg switches to Zepbound 10mg = same dose, same molecule, just different brand label. No retitration needed. Switch driven by insurance change or indication shift.

Practical note: pens look identical except for branding. Patients can switch without learning new injection technique. Schedule and dose unchanged.

Insurance angle: when switching, the new brand requires new PA documentation. Plan ahead to avoid coverage gap during the switch.